Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 4Urinary Bladder Neoplasms 3Pancreatic Neoplasms 3Colonic Neoplasms 2Cholangiocarcinoma 2Tongue Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Lymphoid Interstitial Pneumonia 1Klatskin Tumor 1HIV Infections 1Gastrointestinal Neoplasms 1Gallbladder Neoplasms 1Fallopian Tube Neoplasms 1Epstein-Barr Virus Infections 1Endometrial Neoplasms 1DNA Repair-Deficiency Disorders 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Clinical Stage I Gastric Cancer AJCC v8 1Clinical Stage I Esophageal Adenocarcinoma AJCC v8 1Anus Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Oxaliplatin 8Fluorouracil 8Nivolumab 7Leucovorin 7Paclitaxel 6Capecitabine 5Taxes 4Specimen Handling 4pembrolizumab 3Trastuzumab 3Ramucirumab 3Magnetic Resonance Spectroscopy 3Cisplatin 3zimberelimab 2zanidatamab 2Radiotherapy 2Folfox protocol 2Carboplatin 2zolbetuximab 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1tislelizumab 1quemliclustat 1obeticholic acid 1futibatinib 1dehydroftorafur 1cixutumumab 1balstilimab 1Saline Solution 1Radiofrequency Ablation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma Of Esophagus × dehydroftorafur × 30 days × Clear all
NCT05677490 2026-05-08

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Alliance for Clinical Trials in Oncology

Phase 3 Recruiting
382 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡